Critical Issues in Head and Neck Oncology
portes grátis
Critical Issues in Head and Neck Oncology
Key Concepts from the Ninth THNO Meeting
Leemans, C. Rene; Nicolai, Piero; Vermorken, Jan B.; Langendijk, Johannes A.; Machiels, Jean-Pascal; O'Sullivan, Brian
Springer International Publishing AG
06/2025
459
Dura
Inglês
9783031845383
Pré-lançamento - envio 15 a 20 dias após a sua edição
Descrição não disponível.
Section 1: From basic science to clinical application.- 1. Oral potentially malignant disorders (OPMD): an update, Ruud Brakenhoff.- 2. The role of artificial intelligence in OPMD.- 3. Treatment of OPMD and first results of immune checkpoint inhibitors.- 4. Innovations in cell-based assays for drug discovery and drug evaluation.- 5. Is the ESCAT ranking of support in head and neck cancer management?.- 6. Mechanism of action and potential use of SMAC mimetics in HNSCC.- 7. Precision medicine beyond genomics.- Section 2: Primary disease.- 8. Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?.- 9. Partial laryngeal surgery in 2023.- 10. Managing the internal carotid artery in head and neck cancer: where are we?.- 11. Improving quality of reconstructive surgery in head and neck cancer.- 12. Innovation in radiotherapy: "FLASH-therapy".- 13. Hypoxia in head and neck cancer: current relevance.- 14. Hyperthermia: a game changer in the management of head and neck cancer?.- Section 3: Primary disease.- 15. Prognostic factors in HPV-positive oropharyngeal cancer: an update.- 16. Immunotherapy and novel agents in locoregionally advanced HNSCC.- 17. Is reducing the extent of local treatments justified after successful neoadjuvant therapy?.- 18. Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC.- 19. Innovations in head and neck surgery in the 21st century.- 20. Impact of emerging technology developments in proton therapy.- Section 4: Recurrent/Metastatic (R/M) disease.- 21. 50 years of systemic therapy: what have we gained?.- 22. The potential roles of Antibody-Drug Conjugates in head and neck cancer.- 23. Intratumoral drug administration: more potential in head and neck cancer?.- 24. Novel radioenhancer NBTXR3 as a single agent in locally advanced (LA) HNSCC or in combination with anti-PD1 in R/M HNSCC.- 25. Metronomic chemotherapy and immunotherapy: a fascinating approach.- 26. Metastatic head and neck cancer: what is the optimal local treatment?.- Section 5: Salivary Gland cancer.- 27. Molecular characterization of salivary gland cancer and treatment implications.- 28. Salivary duct carcinoma: strategies to improve outcome.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Nasopharynx cancer;Head and Neck Cancer;Radiation Oncology;Surgical Oncology;Head and Neck Squamous Cell Cancer;Oro-Pharyngeal Head and Neck Cancer;Predictive Markers;Liquid Biopsies;Induction Chemotherapy;Immunotherapy;Precision Medicine;HNSCC;Open Access;Surgery;Radiation;Chemotherapy;Immunotherapy;Open Access
Section 1: From basic science to clinical application.- 1. Oral potentially malignant disorders (OPMD): an update, Ruud Brakenhoff.- 2. The role of artificial intelligence in OPMD.- 3. Treatment of OPMD and first results of immune checkpoint inhibitors.- 4. Innovations in cell-based assays for drug discovery and drug evaluation.- 5. Is the ESCAT ranking of support in head and neck cancer management?.- 6. Mechanism of action and potential use of SMAC mimetics in HNSCC.- 7. Precision medicine beyond genomics.- Section 2: Primary disease.- 8. Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?.- 9. Partial laryngeal surgery in 2023.- 10. Managing the internal carotid artery in head and neck cancer: where are we?.- 11. Improving quality of reconstructive surgery in head and neck cancer.- 12. Innovation in radiotherapy: "FLASH-therapy".- 13. Hypoxia in head and neck cancer: current relevance.- 14. Hyperthermia: a game changer in the management of head and neck cancer?.- Section 3: Primary disease.- 15. Prognostic factors in HPV-positive oropharyngeal cancer: an update.- 16. Immunotherapy and novel agents in locoregionally advanced HNSCC.- 17. Is reducing the extent of local treatments justified after successful neoadjuvant therapy?.- 18. Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC.- 19. Innovations in head and neck surgery in the 21st century.- 20. Impact of emerging technology developments in proton therapy.- Section 4: Recurrent/Metastatic (R/M) disease.- 21. 50 years of systemic therapy: what have we gained?.- 22. The potential roles of Antibody-Drug Conjugates in head and neck cancer.- 23. Intratumoral drug administration: more potential in head and neck cancer?.- 24. Novel radioenhancer NBTXR3 as a single agent in locally advanced (LA) HNSCC or in combination with anti-PD1 in R/M HNSCC.- 25. Metronomic chemotherapy and immunotherapy: a fascinating approach.- 26. Metastatic head and neck cancer: what is the optimal local treatment?.- Section 5: Salivary Gland cancer.- 27. Molecular characterization of salivary gland cancer and treatment implications.- 28. Salivary duct carcinoma: strategies to improve outcome.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Nasopharynx cancer;Head and Neck Cancer;Radiation Oncology;Surgical Oncology;Head and Neck Squamous Cell Cancer;Oro-Pharyngeal Head and Neck Cancer;Predictive Markers;Liquid Biopsies;Induction Chemotherapy;Immunotherapy;Precision Medicine;HNSCC;Open Access;Surgery;Radiation;Chemotherapy;Immunotherapy;Open Access
